Given immunohistochemistry results showing CK‑20 (cytokeratin 20) positive, CDX‑2 (caudal type homeobox 2) positive, SATB2 (special AT‑rich sequence‑binding protein 2) positive, PAX‑8 (paired box gene 8) negative, and CK‑7 (cytokeratin 7) negative, what is the most likely primary tumor and what are the appropriate next diagnostic and management steps?

Primary Tumor Diagnosis: Colorectal Adenocarcinoma

This immunohistochemistry profile (CK20+, CDX2+, SATB2+, PAX-8−, CK7−) is diagnostic of colorectal adenocarcinoma with >95% certainty. 1, 2

Interpretation of Immunohistochemistry Results

The immunophenotype presented represents the classic colorectal cancer signature:

• CK7−/CK20+/CDX2+ is the hallmark pattern seen in at least 80% of colorectal carcinomas 1, 3
• SATB2 positivity provides 93-97% specificity for lower gastrointestinal origin, particularly when combined with CK20 1, 2, 4
• PAX-8 negativity effectively excludes gynecologic primaries (ovarian, endometrial) and upper urinary tract origins 5, 6
• CK7 negativity further excludes pancreaticobiliary, upper GI, lung, breast, and most gynecologic primaries 1

The combination of SATB2+ with CK20+ identifies 97% of all colorectal carcinomas 2, and this dual positivity pattern is highly specific (88-98%) for colorectal origin 4.

Alternative Diagnostic Consideration

Appendiceal mucinous adenocarcinoma shares an identical immunoprofile (CK20+, CDX2+, SATB2+, PAX-8−, CK7−) and must be considered in the differential diagnosis 5, 6. SATB2 is positive in 93.8% of appendiceal tumors with 97.5% specificity 6. Clinical correlation is essential to distinguish between these two lower GI primaries.

Next Diagnostic Steps

Immediate Clinical Evaluation

1. Obtain detailed history focusing on:

   • Prior colonoscopy results and dates
   • Gastrointestinal symptoms (bleeding, change in bowel habits, obstruction)
   • History of appendicitis or appendectomy 5
   • Family history of colorectal cancer

2. Tumor marker assessment:

   • CEA (carcinoembryonic antigen) - elevated in most colorectal cancers 1
   • CA19-9 and CA72-4 when GI primary suspected 1
   • Markedly elevated CEA with mucinous features suggests appendiceal origin 5

Imaging Protocol

Mandatory imaging per ESMO guidelines 1:

• CT chest/abdomen/pelvis with IV contrast (or MRI if contrast contraindicated)
• Focus on identifying:
  • Primary colonic mass or appendiceal abnormality
  • Extent of metastatic disease
  • Peritoneal involvement (suggests appendiceal primary if diffuse mucinous ascites present) 5

Endoscopic Evaluation

Colonoscopy is mandatory to:

• Identify and biopsy primary colorectal lesion
• Assess tumor location, size, and degree of obstruction
• Rule out synchronous lesions (present in 3-5% of cases)

If colonoscopy is negative or incomplete and appendiceal primary suspected, consider CT colonography or capsule endoscopy.

Management Algorithm

If Primary Colorectal Lesion Identified

1. Complete staging:

   • Clinical TNM staging based on imaging
   • Assess resectability of primary and metastases
   • Determine if synchronous metastatic disease present

2. Molecular testing on tumor tissue:

   • RAS/BRAF mutation status (guides anti-EGFR therapy eligibility)
   • MMR/MSI status (predicts immunotherapy response) 3
   • HER2 amplification (emerging therapeutic target)
   • NTRK fusion (rare but actionable) 3

3. Treatment approach:

   • Resectable disease: Primary tumor resection followed by adjuvant chemotherapy if node-positive or high-risk stage II
   • Metastatic disease: Systemic chemotherapy (FOLFOX/FOLFIRI ± biologics based on molecular profile), consider metastasectomy if oligometastatic

If Appendiceal Primary Suspected

Clinical red flags for appendiceal origin 5:

• Bilateral ovarian masses with mucinous features
• Peritoneal carcinomatosis with mucinous ascites
• Markedly elevated CEA (often >100 ng/mL)
• History of appendicitis
• Poor response to standard colorectal chemotherapy regimens

Management differs significantly:

• Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease
• FOLFOX-based systemic therapy
• Requires specialized center with peritoneal surface malignancy expertise

Critical Pitfalls to Avoid

1. Do not assume ovarian primary in women with pelvic masses and this immunoprofile - PAX-8 negativity with CK20+/CDX2+/SATB2+ essentially excludes primary ovarian origin 5, 6

2. Do not overlook appendiceal primary - requires specific surgical approach (cytoreduction + HIPEC) rather than standard colorectal protocols 5

3. Rare upper GI and pancreaticobiliary adenocarcinomas can occasionally show colorectal immunophenotype, but SATB2 positivity strongly favors lower GI origin 1

4. Ensure adequate tissue for molecular testing before initiating therapy - RAS/BRAF status is essential for treatment planning and cannot be reliably assessed on liquid biopsy alone in treatment-naive patients